Investigating the effects of yoga on adults with cystic fibrosis
Yoga Outcomes Get Assessed in Cystic Fibrosis
This study is testing whether a 12-week yoga program can improve the quality of life for adults with cystic fibrosis when combined with their usual care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 314 (estimated) |
| Ages | 16 Years and up |
| Sex | All |
| Sponsor | Royal Brompton & Harefield NHS Foundation Trust Academic / other |
| Locations | 1 site (London, Greater London) |
| Trial ID | NCT06120465 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to explore how participation in a 12-week yoga program influences health-related quality of life for adults diagnosed with cystic fibrosis. Participants will be divided into two groups: one receiving the yoga intervention alongside standard cystic fibrosis care, and the other receiving standard care alone. The study will assess the impact of yoga on various health metrics to determine its effectiveness as a complementary therapy for this condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 16 and over with a confirmed diagnosis of cystic fibrosis who have stable disease and can complete questionnaires in English.
Not a fit: Patients currently experiencing severe respiratory issues, participating in other interventional studies, or with certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the quality of life for adults living with cystic fibrosis through the incorporation of yoga into their treatment regimen.
How similar studies have performed: While yoga has been explored in various health contexts, this specific approach for cystic fibrosis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Diagnosis of CF (confirmed by standard criteria; (Farrell et al. 2017)) Sixteen years of age or over Home internet access Ability to complete questionnaires in English Stable CF disease as judged by the investigator, a senior CF clinician Exclusion Criteria: Inability to consent for treatment or measurement Current participation in another interventional study Current haemoptysis (greater than streaking in the sputum) Known pregnancy at time of recruitment Forced expiratory volume in 1 second (FEV1) below 30% predicted at baseline Use of ambulatory oxygen therapy, long-term oxygen therapy (LTOT) or non-invasive ventilation Current regular participation in yoga practice Current neurological or musculoskeletal injury which would prevent completion of yoga Diagnosis of osteoporosis (bone density Z score \<-2.5) or history of spontaneous spinal fractures Uncontrolled gastroesophageal reflux Acute pulmonary exacerbation within 28 days of screening
Where this trial is running
London, Greater London
- The Royal Brompton Hospital — London, Greater London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Nicholas Simmonds — Royal Brompton Hospital, Guys and St Thomas's Foundation Trust
- Study coordinator: Gemma Stanford
- Email: g.stanford@rbht.nhs.uk
- Phone: 0207 3528121
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.